Evidence map›Paper›PMID 36263060›Full record

ArticlebioRxiv : the preprint server for biology2022

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.

Suzanne M Scheaffer, Diana Lee, Bradley Whitener, Baoling Ying, Kai Wu, Hardik Jani, Philippa Martin, Nicholas J Amato, Laura E Avena, Daniela Montes Berrueta and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 26 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Suzanne M ScheafferDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Diana LeeModerna, Inc., Cambridge MA, USA.
Bradley WhitenerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Baoling YingDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Kai WuModerna, Inc., Cambridge MA, USA.
Hardik JaniModerna, Inc., Cambridge MA, USA.
Philippa MartinModerna, Inc., Cambridge MA, USA.
Nicholas J AmatoModerna, Inc., Cambridge MA, USA.
Laura E AvenaModerna, Inc., Cambridge MA, USA.
Daniela Montes BerruetaModerna, Inc., Cambridge MA, USA.
Stephen D SchmidtVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Sijy O'DellVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Arshan NasirModerna, Inc., Cambridge MA, USA.
Gwo-Yu ChuangModerna, Inc., Cambridge MA, USA.
Guillaume Stewart-JonesModerna, Inc., Cambridge MA, USA.
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Andrea CarfiModerna, Inc., Cambridge MA, USA.
Sayda M ElbashirModerna, Inc., Cambridge MA, USA.
Larissa B ThackrayDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Darin K EdwardsModerna, Inc., Cambridge MA, USA.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Moderna Therapeutics (United States) · USWashington University in St. Louis · USNational Institute of Allergy and Infectious Diseases · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI157155
6 · The paper itself

Abstract

The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bivalent vaccines that encode for spike proteins from both historical and newly-emerged variant strains. Here, we evaluated the immunogenicity and protective efficacy of two bivalent vaccines that recently were authorized for use in Europe and the United States and contain two mRNAs encoding Wuhan-1 and either BA.1 (mRNA-1273.214) or BA.4/5 (mRNA-1273.222) spike proteins. As a primary immunization series in BALB/c mice, both bivalent vaccines induced broader neutralizing antibody responses than the constituent monovalent vaccines (mRNA-1273 [Wuhan-1], mRNA-1273.529 [BA.1], and mRNA-1273-045 [BA.4/5]). When administered to K18-hACE2 transgenic mice as a booster at 7 months after the primary vaccination series with mRNA-1273, the bivalent vaccines induced greater breadth and magnitude of neutralizing antibodies compared to an mRNA-1273 booster. Moreover, the response in bivalent vaccine-boosted mice was associated with increased protection against BA.5 infection and inflammation in the lung. Thus, boosting with bivalent Omicron-based mRNA-1273.214 or mRNA-1273.222 vaccines enhances immunogenicity and protection against currently circulating SARS-CoV-2 strains.

Identifiers

PMID36263060
PMCPMC9580377
OpenAlexW4295838554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.